The Presidential Veto Within two years, DePinho had vetoed more tenure renewals than the previous president, John Mendelsohn, had in seven. Recent denials of tenure in cases where applicants received unanimous recommendations from the PTC prompted the Executive Committee of the Faculty Senate to investigate the renewal process. “There has been some concern that the... […]
A year before Kapil Mehta's tenure term expired last August, the 11-member Promotions and Tenure Committee at MD Anderson Cancer Center had unanimously recommended renewal.
The Department of Defense announced the availability of several grants through its Ovarian Cancer Research Program and its Lung Cancer Research Program.
The American Cancer Society prefers to avoid public confrontation with corporate donors, even those who make money by selling tobacco products.
When CVS made the decision to forego tobacco sales, the estimated $2 billion in annual revenues it gave up amounts to more than twice the amount of money ACS collects in a year (The Cancer Letter, Feb. 7). However, ACS positions itself as the vanguard of tobacco control, and critics say that close association with a retailer that profits from tobacco undermines the society's own goals and harms its brand.
The Japan Ministry of Health, Labor and Welfare granted approval to the Lonsurf combination tablet T15 and T20 (trifluridine and tipiracil hydrochloride), for the treatment of patients with unresectable advanced or recurrent colorectal cancer, if refractory to standard therapies.
The European Commission approved a subcutaneous formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma.
THE RESEARCH!AMERICA Advocacy Awards was held March 12 in Washington, D.C., recognizing individuals and organizations are those whose leadership efforts have been notably effective in advancing our nation's commitment to research.
THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO signed an agreement with Advaxis Inc. to evaluate several new immunotherapy constructs, each built on Advaxis proprietary technology.
THE AMERICAN SOCIETY OF HEMATOLOGY announced 15 research investigators who will receive critical interim support for hematology research proposals that, despite earning high scores, could not be funded by the NIH amid severe funding reductions.
